Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AramarkARMK · Entity 3359 | Director | August 29, 2019 | September 04, 2019 |
| CHESAPEAKE UTILITIES CORPCPK · Entity 4195 | Director | May 06, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aramark
Report date August 29, 2019 · Filed September 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,603.4045 |
Reported balance
After 2019-08-29 transaction · row 1
1 source rowRow 1 · 2019-08-29 · Grant · Acquired 61 · Balance 22,603.4045 F1: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards.
CHESAPEAKE UTILITIES CORP
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,932 |
Reported balance
After 2026-05-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 1,112 · Balance 4,932 F1: Shares issued for director compensation under the Company's Stock Incentive and Compensation Plan. F2: Includes 4,590 deferred stock units of which 1,112 are from the reported award and 38 were acquired by the reporting person since the last filing through reinvestment of dividends pursuant to a dividend reinvestment plan. Deferred stock units will be settled on a one-for-one basis in common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued for director compensation under the Company's Stock Incentive and Compensation Plan.
F2: Includes 4,590 deferred stock units of which 1,112 are from the reported award and 38 were acquired by the reporting person since the last filing through reinvestment of dividends pursuant to a dividend reinvestment plan. Deferred stock units will be settled on a one-for-one basis in common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CVS HEALTH Corp
Report date February 01, 2021 · Filed April 02, 2021
Section 16 reporting ended · disclosed 2021-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,103 |
Reported balance
After 2021-02-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2021-02-01 · Grant · Acquired 77,457 · Balance 100,103 F1: Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on February 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 1, 2021. The PSUs vested and settled on April 1, 2021. |
| Common StockSEC Table I · non-derivative | Direct | 64,983 |
Reported balance
After 2021-04-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2021-04-01 · Tax withholding · Disposed 35,120 · Balance 64,983 F2: Surrender of shares in payment of taxes due upon the vesting and settlement of the PSUs on April 1, 2021. |
| Common StockSEC Table I · non-derivative | Direct | 66,417 |
Reported balance
After 2021-04-01 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2021-04-01 · Tax withholding · Disposed 1,190 · Balance 66,417 F3: Surrender of shares in payment of taxes due upon the vesting and settlement of a restricted stock unit award on April 1, 2021. |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 23,942 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,942 |
| Common Stock (restricted)SEC Table I · non-derivative | Direct | 3,523 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,523 |
| ESOP Common StockSEC Table I · non-derivative | IndirectDirect | 655 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 655 |
| Stock UnitSEC Table I · non-derivative | Direct | 32,145.773 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 32,145.773 |
| Phantom Stock CreditsSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 469.0358 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 469.0358 F4: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. F5: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $102.26 · Expires 2022-04-01 | Direct | 34,241 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 34,241 F6: Option became exercisable in four equal annual installments, commencing 4/1/2016. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $104.82 · Expires 2023-04-01 | Direct | 39,433 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 39,433 F7: Option became exercisable in four equal annual installments, commencing 4/1/2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $78.05 · Expires 2024-04-03 | Direct | 55,098 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 55,098 F8: Option became exercisable in four equal annual installments, commencing 4/3/2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $62.21 · Expires 2025-04-01 | Direct | 64,222 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 64,222 F9: Option became exercisable in four equal annual installments, commencing 4/1/2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $54.19 · Expires 2029-04-01 | Direct | 141,405 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 141,405 F10: Option became exercisable in four equal annual installments, commencing 4/1/2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $58.34 · Expires 2030-04-01 | Direct | 98,558 |
Reported balance
Holding disclosure · report date 2021-02-01 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 98,558 F11: The number of shares subject to the option were calculated using a 30-day average price. F12: Options became exercisable in four equal annual installments, commencing 4/1/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on February 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 1, 2021. The PSUs vested and settled on April 1, 2021.
F2: Surrender of shares in payment of taxes due upon the vesting and settlement of the PSUs on April 1, 2021.
F3: Surrender of shares in payment of taxes due upon the vesting and settlement of a restricted stock unit award on April 1, 2021.
F4: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F5: Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F6: Option became exercisable in four equal annual installments, commencing 4/1/2016.
F7: Option became exercisable in four equal annual installments, commencing 4/1/2017.
F8: Option became exercisable in four equal annual installments, commencing 4/3/2018.
F9: Option became exercisable in four equal annual installments, commencing 4/1/2019.
F10: Option became exercisable in four equal annual installments, commencing 4/1/2020.
F11: The number of shares subject to the option were calculated using a 30-day average price.
F12: Options became exercisable in four equal annual installments, commencing 4/1/2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2026 Filed May 8, 2026 20:20 UTC | CHESAPEAKE UTILITIES CORP CPK · Entity 4195 | GrantCommon Stock | 1,112 | $125.83 | $139,922.96 |
DisclosureSEC source: 0001479663-26-000003 · wk-form4_1778271630.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,932 F1 · shares: Shares issued for director compensation under the Company's Stock Incentive and Compensation Plan. F2 · balance_after: Includes 4,590 deferred stock units of which 1,112 are from the reported award and 38 were acquired by the reporting person since the last filing through reinvestment of dividends pursuant to a dividend reinvestment plan. Deferred stock units will be settled on a one-for-one basis in common stock. Read SEC document |
| May 07, 2025 Filed May 9, 2025 19:44 UTC | CHESAPEAKE UTILITIES CORP CPK · Entity 4195 | GrantCommon Stock | 895 | $134.05 | $119,974.75 |
DisclosureSEC source: 0000019745-25-000021 · primary_doc.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,746 F1 · balance_after: Includes 3,404 deferred stock units of which 895 are from the reported award and 26 were acquired by the reporting person since the last filing through reinvestment of dividends pursuant to a dividend reinvestment plan. Deferred stock units will be settled on a one-for-one basis in common stock. Read SEC document |
| May 08, 2024 Filed May 10, 2024 22:44 UTC | CHESAPEAKE UTILITIES CORP CPK · Entity 4195 | GrantCommon Stock | 995 | $110.53 | $109,977.35 |
DisclosureSEC source: 0000019745-24-000027 · primary_doc.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,797 F1 · balance_after: Includes 2,455 deferred stock units, of which 16 were acquired by the reporting person since the last filing through reinvestment of dividends pursuant to a dividend reinvestment plan. Deferred stock units will be settled on a one-for-one basis in common stock. Read SEC document |
| May 03, 2023 Filed May 6, 2023 00:11 UTC | CHESAPEAKE UTILITIES CORP CPK · Entity 4195 | GrantCommon Stock | 765 | $124.12 | $94,951.80 |
DisclosureSEC source: 0000019745-23-000029 · primary_doc.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,770 F1 · balance_after: Includes 1,428 deferred stock units, of which 6 were acquired by the reporting person since the last filing through reinvestment of dividends pursuant to a dividend reinvestment plan. Deferred stock units will be settled on a one-for-one basis in common stock. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:22 UTC | CHESAPEAKE UTILITIES CORP CPK · Entity 4195 | GrantCommon Stock | 652 | $130.36 | $84,994.72 |
DisclosureSEC source: 0001228532-22-000026 · primary_doc.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994 F1 · balance_after: Includes 652 deferred stock units that will be settled on a one-for-one basis in common stock. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:57 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 1,190 | $74.30 | $88,417.00 |
DisclosureSEC source: 0001127602-21-012689 · form4.xml · nonDerivative · entry 3 Bisaccia Lisa · CIK 0001479663 · Former EVP & Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,417 F3 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of a restricted stock unit award on April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:57 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 35,120 | $74.30 | $2,609,416.00 |
DisclosureSEC source: 0001127602-21-012689 · form4.xml · nonDerivative · entry 2 Bisaccia Lisa · CIK 0001479663 · Former EVP & Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,983 F2 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of the PSUs on April 1, 2021. Read SEC document |
| February 01, 2021 Filed Apr 2, 2021 20:57 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 77,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012689 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Former EVP & Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,103 F1 · shares: Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on February 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 1, 2021. The PSUs vested and settled on April 1, 2021. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 22:08 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 25,177 | $0.00 Strike: $74.29 | $0.00 |
DisclosureSEC source: 0001127602-21-001603 · form4.xml · derivative · entry 6 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,177 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2015. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 22:08 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 25,177 | $77.00 | $1,938,629.00 |
DisclosureSEC source: 0001127602-21-001603 · form4.xml · nonDerivative · entry 2 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,588 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 22:08 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 25,177 | $74.29 | $1,870,399.33 |
DisclosureSEC source: 0001127602-21-001603 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:45 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 1,598 | $55.72 | $89,040.56 |
DisclosureSEC source: 0001127602-20-013419 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,588 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 98,558 | $58.61 Strike: $58.61 | $5,776,484.38 |
DisclosureSEC source: 0001127602-20-013233 · form4.xml · derivative · entry 5 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,558 Underlying: Common Stock · 98,558 shares Expires 2030-04-01 F2 · derivative.exercise_price: The number of shares subject to the option were calculated using a 30-day average price. F3 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2021. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:29 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 1,109 | $58.34 | $64,699.06 |
DisclosureSEC source: 0001127602-20-013233 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,663 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2020 Filed Apr 7, 2020 21:38 UTC Amendment | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 98,558 | $0.00 Strike: $58.34 | $0.00 |
DisclosureSEC source: 0001127602-20-013409 · form4a.xml · derivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,558 Underlying: Common Stock · 98,558 shares Expires 2030-04-01 F1 · derivative.exercise_price: This Form 4/A is being filed in order to correct the exercise price (Table II, column 2) for the stock option granted on 4/1/2020, which was reported incorrectly on the original Form 4 due to a clerical error. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:32 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 6,202 | $59.18 | $367,034.36 |
DisclosureSEC source: 0001127602-20-009151 · form4.xml · nonDerivative · entry 2 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,327 F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of stock awards under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:32 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 18,587 | $59.18 | $1,099,978.66 |
DisclosureSEC source: 0001127602-20-009151 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,529 F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| August 29, 2019 Filed Sep 4, 2019 01:29 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 61 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-19-000174 · wf-form4_156756057170689.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,603.4045 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 22:19 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 70.848 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-19-000128 · wf-form4_155960032572062.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,542.4045 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:56 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 141,405 | $54.19 Strike: $54.19 | $7,662,736.95 |
DisclosureSEC source: 0001127602-19-014672 · form4.xml · derivative · entry 5 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,405 Underlying: Common Stock · 141,405 shares Expires 2029-04-01 F2 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:56 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 2,411 | $54.19 | $130,652.09 |
DisclosureSEC source: 0001127602-19-014672 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,942 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under an incentive compensation plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:41 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 81.284 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-19-000066 · wf-form4_155173569535094.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,471.5565 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:54 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 3,015 | $57.83 | $174,357.45 |
DisclosureSEC source: 0001127602-19-009283 · form4.xml · nonDerivative · entry 2 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,023 F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:54 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 6,952 | $57.83 | $402,034.16 |
DisclosureSEC source: 0001127602-19-009283 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,038 F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:37 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 4,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-19-000022 · wf-form4_154905702924559.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,390.2725 F1 · price: Represents a grant of deferred stock units, which will vest on the day prior to the first annual stockholders' meeting of the Company occurring after the grant date, subject to continued service, and, if vested, will be settled in shares of common stock on the first day of the seventh month after the date of the director's departure from the board. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 22:03 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 50.928 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-18-000260 · wf-form4_154447936527596.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,482.2725 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 13,770 | $0.00 Strike: $54.53 | $0.00 |
DisclosureSEC source: 0001127602-18-029360 · form4.xml · derivative · entry 9 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,770 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2014. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 7,764 | $0.00 Strike: $45.07 | $0.00 |
DisclosureSEC source: 0001127602-18-029360 · form4.xml · derivative · entry 8 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,764 shares Expires 2019-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/2/2013. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 13,770 | $80.00 | $1,101,600.00 |
DisclosureSEC source: 0001127602-18-029360 · form4.xml · nonDerivative · entry 4 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,086 F1 · kind: All transactions were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 13,770 | $54.53 | $750,878.10 |
DisclosureSEC source: 0001127602-18-029360 · form4.xml · nonDerivative · entry 3 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 7,764 | $80.00 | $621,120.00 |
DisclosureSEC source: 0001127602-18-029360 · form4.xml · nonDerivative · entry 2 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,086 F1 · kind: All transactions were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:07 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 7,764 | $45.07 | $349,923.48 |
DisclosureSEC source: 0001127602-18-029360 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 22:55 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 44.583 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-18-000170 · wf-form4_153610168927686.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,431.3445 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:10 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 46.901 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-18-000117 · wf-form4_152815019138131.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,386.7615 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 64,222 | $62.21 Strike: $62.21 | $3,995,250.62 |
DisclosureSEC source: 0001127602-18-013817 · form4.xml · derivative · entry 5 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,222 Underlying: Common Stock · 64,222 shares Expires 2025-04-01 F2 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2019. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 2,162 | $62.21 | $134,498.02 |
DisclosureSEC source: 0001127602-18-013817 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,086 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under an incentive compensation plan. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:51 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 44.423 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-18-000062 · wf-form4_152028668173335.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,339.8605 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:59 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 885 | $67.73 | $59,941.05 |
DisclosureSEC source: 0001127602-18-009719 · form4.xml · nonDerivative · entry 2 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,594 F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under the Registrant's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:59 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 2,923 | $67.73 | $197,974.79 |
DisclosureSEC source: 0001127602-18-009719 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,479 F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:14 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 3,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-18-000029 · wf-form4_151760602674703.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,295.4375 F1 · price: Represents a grant of deferred stock units, which will vest on the day prior to the first annual stockholders' meeting of the Company occurring after the grant date, subject to continued service, and, if vested, will be settled in shares of common stock on the first day of the seventh month after the date of the director's departure from the board. Read SEC document |
| January 05, 2018 Filed Jan 10, 2018 00:01 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 292 | $42.72 | $12,474.24 |
DisclosureSEC source: 0001584509-18-000009 · wf-form4_151554246587425.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,802.4375 F1 · price: Represents a grant of fully vested deferred stock units into which the director has elected to defer all of her cash retainer, which will be settled in shares of common stock on the first day of the seventh month after the date of the director's departure from the board. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:39 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 29,445 | $75.00 | $2,208,375.00 |
DisclosureSEC source: 0001127602-17-035452 · form4.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,556 F1 · kind: All transactions were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 23:06 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 33.2652 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-17-000265 · wf-form4_151303357169325.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,510.4375 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| October 07, 2017 Filed Oct 10, 2017 21:04 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 301 | $41.42 | $12,467.42 |
DisclosureSEC source: 0001584509-17-000206 · wf-form4_150766945149532.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,477.1723 F1 · price: Represents a grant of fully vested deferred stock units into which the director has elected to defer a portion of her cash retainer, which will be settled in shares of common stock on the first day of the seventh month after the date of the director's departure from the board. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 22:12 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 33.5819 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-17-000186 · wf-form4_150482233914441.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,176.1723 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 21:16 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 310 | $40.24 | $12,474.40 |
DisclosureSEC source: 0001584509-17-000152 · wf-form4_149980779342680.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,142.5904 F1 · price: Represents a grant of fully vested deferred stock units into which the director has elected to defer all of her cash retainer, which will be settled in shares of common stock on the first day of the seventh month after the date of the director's departure from the board. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 21:17 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 33.776 | $0.00 | $0.00 |
DisclosureSEC source: 0001584509-17-000123 · wf-form4_149695664242656.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,832.5904 F1 · shares: Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 21:19 UTC | Aramark ARMK · Entity 3359 | GrantCommon Stock | 342 | $36.46 | $12,469.32 |
DisclosureSEC source: 0001584509-17-000089 · wf-form4_149194556069268.xml · nonDerivative · entry 1 Bisaccia Lisa · CIK 0001479663 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,798.8144 F1 · price: Represents a grant of fully vested deferred stock units into which the director has elected to defer all of her cash retainer, which will be settled in shares of common stock on the first day of the seventh month after the date of the director's departure from the board. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 55,098 | $78.05 Strike: $78.05 | $4,300,398.90 |
DisclosureSEC source: 0001127602-17-014066 · form4.xml · derivative · entry 6 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,098 Underlying: Common Stock · 55,098 shares Expires 2024-04-03 F3 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/3/2018. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (restricted) | 7,046 | $78.05 | $549,940.30 |
DisclosureSEC source: 0001127602-17-014066 · form4.xml · nonDerivative · entry 3 Bisaccia Lisa · CIK 0001479663 · EVP and Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,084.0004 F2 · shares: Consists of restricted stock units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 50% on 4/3/2020 and 50% on 4/3/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.